



November 26, 2019

DePuy Orthopaedics, Inc.
% Susan Mullane
Regulatory Affairs Project Leader
DePuy (Ireland)
Loughbeg, Ringaskiddy
CORK, P43ED82
IRELAND

Re: K192946

Trade/Device Name: DePuy Corail AMT Hip Prosthesis
Regulation Number: 21 CFR 888.3353
Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous
Uncemented Prosthesis
Regulatory Class: Class II
Product Code: LZO, MEH, KWL, KWY,
Dated: October 17, 2019
Received: October 18, 2019

Dear Susan Mullane:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for

Vesa Vuniqui
Assistant Director
DHT6A: Division of Joint Arthroplasty Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K192946

Device Name

DePuy Corail AMT Hip Prosthesis

Indications for Use (Describe)

Total hip replacement or hip arthroplasty is indicated in the following conditions:

1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.
2. Avascular necrosis of the femoral head.
3. Acute traumatic fracture of the femoral head or neck.
4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemi-arthroplasty, surface replacement arthroplasty, or total hip replacement.
5. Certain cases of ankyloses.

Partial hip replacement or hip hemi-arthroplasty is indicated in the following conditions:

1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation.
2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation.
3. Avascular necrosis of the femoral head.
4. Non-union of femoral neck fractures.
5. Certain high subcapital and femoral neck fractures in the elderly.
6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement.
7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemi-arthroplasty.

HA coated stems of the Corail Hip system are indicated for cementless use only.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(K) SUMMARY

(As required by 21 CFR 807.92 and 21 CFR 807.93)

Submitter Information	
Name	DePuy Ireland Ltd.
Address	Loughbeg, Ringaskiddy, Co.Cork, Ireland
Phone number	00 353 21 4914110
Fax number	N/A
Establishment Registration #	9616671
Name of contact person	Susan Mullane
Date prepared	15 October 2019
Name of device	
Trade or proprietary name	DePuy Corail AMT Hip Prosthesis
Common or usual name	Uncemented hip prosthesis
Classification name	Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis
Class	II
Classification panel	87 Orthopedics
Regulation	21 CFR 888.5535, 888.3360, 888.3390
Product Code(s)	LZO, MEH, KWL, KWY

Legally marketed device(s) to which equivalence is claimed	DePuy Corail AMT Hip Prosthesis (K042992, K070554, K093736, K123991, K173960)
Reason for 510(k) submission	The purpose of this submission is to support the manufacturing and sterilization of the subject, Hydroxyapatite (HA) coated DePuy Corail AMT Hip Prosthesis components at an alternate manufacturing and sterilization facility. The packaging has been slightly modified. There are no other modifications associated with this product in comparison with the currently marketed predicate DePuy Corail AMT Hip Prosthesis – the predicate and proposed devices share the same intended use, product design, principle of operation, and materials.
Device description	The DePuy Corail AMT hip stem family are manufactured from forged titanium alloy (Ti6Al4V) and plasma-sprayed with a hydroxyapatite (HA) coating for bone fixation. The stem consists of a wide range of stem neck designs and sizes allowing an accurate anatomical match for each patient. Corail AMT stems are available with or without a collar, with various neck angles, and with various neck offsets.
Intended use of the device	Total hip arthroplasty and hemi-hip arthroplasty
Indications for use	Total hip replacement or hip arthroplasty is indicated in the following conditions: A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia. 1. Avascular necrosis of the femoral head. 2. Acute traumatic fracture of the femoral head or neck. 3. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemi-arthroplasty, surface replacement arthroplasty, or total hip replacement.

	4. Certain cases of ankyloses. Partial hip replacement or hip hemi-arthroplasty is indicated in the following conditions: 1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation. 2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation. 3. Avascular necrosis of the femoral head. 4. Non-union of femoral neck fractures. 5. Certain high subcapital and femoral neck fractures in the elderly. 6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement. 7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemi-arthroplasty. HA coated stems of the Corail Hip system are indicated for cementless use only.
--	--

SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE PREDICATE DEVICE						
Characteristics	Subject Device: DePuy Corail AMT Hip Prosthesis	Predicate Device: DePuy Corail AMT Hip Prosthesis (K123991)	Predicate Device: DePuy Corail AMT Hip Prosthesis (K123991)	Reference Device: DePuy Corail Hip System, Revision Stem (K093736)	Predicate Device: DePuy Corail AMT Hip Prosthesis (K070554)	Predicate Device: DePuy Corail AMT Hip Prosthesis (K042992)
Intended Use	Total Hip Arthroplasty, Hemi-Hip Arthroplasty	Same	Same	Total Hip Arthroplasty	Total Hip Arthroplasty	Total Hip Arthroplasty
Material	Ti6Al4V with plasma sprayed HA coating	Same	Same	Same	Same	Same
Fixation	Uncemented	Same	Same	Same	Same	Same
Sterile Method	Gamma	Same	Same	Same	Same	Same
Packaging	Inner Pouch and outer PETG blister with Tyvek peel lid	Double PETG blister with Tyvek peel lid	Double PETG blister with Tyvek peel lid	Double PETG blister with Tyvek peel lid	Double PETG blister with Tyvek peel lid	Double PETG blister with Tyvek peel lid

Shelf Life	5 years	Same	Same	Same	Same	Same
PERFORMANCE DATA						
SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE						
THE FOLLOWING TESTS WERE PERFORMED ON THE DEPUY CORAIL AMT HIP PROSTHESIS TO DEMONSTRATE SUBSTANTIAL EQUIVALENCE OF SAFETY AND EFFICACY WITH THE PREDICATE DEVICES: • BIOLOGICAL SAFETY PER ISO 10993-1 “BIOLOGICAL EVALUATION OF MEDICAL DEVICES PART 1: EVALUATION AND TESTING”. • STERILIZATION VALIDATION PER AAMI ANSI ISO 11137-1: 2006/(R)2010 AND AAMI ANSI ISO 11137-2: 2013 • CHARACTERIZATION TESTING OF HYDROXYAPATITE COATING AS RECOMMENDED PER FDA GUIDANCE: “510(K) INFORMATION NEEDED FOR HYDROXYAPATITE COATED ORTHOPEDIC IMPLANT”						
SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION						
NO CLINICAL TESTS WERE CONDUCTED TO DEMONSTRATE SUBSTANTIAL EQUIVALENCE.						
CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA						
THE SUBJECT DEPUY CORAIL AMT HIP PROSTHESIS PRODUCTS ARE SUBSTANTIALLY EQUIVALENT TO THE PREDICATE DEPUY CORAIL AMT HIP PROSTHESIS PRODUCTS ((K042992, K070554, K093736, K123991, K173960))						